TY  - JOUR
AU  - Jones, Katie Fitzgerald
AU  - White, Gretchen
AU  - Bennett, Antonia
AU  - Bulls, Hailey
AU  - Escott, Paula
AU  - Orris, Sarah
AU  - Escott, Elizabeth
AU  - Fischer, Stacy
AU  - Hamm, Megan
AU  - Krishnamurti, Tamar
AU  - Wong, Risa
AU  - LeBlanc, Thomas W
AU  - Liebschutz, Jane
AU  - Meghani, Salimah
AU  - Smith, Cardinale
AU  - Temel, Jennifer
AU  - Ritchie, Christine
AU  - Merlin, Jessica S
PY  - 2024
DA  - 2024/3/13
TI  - Benefits, Harms, and Stakeholder Perspectives Regarding Opioid Therapy for Pain in Individuals With Metastatic Cancer: Protocol for a Descriptive Cohort Study
JO  - JMIR Res Protoc
SP  - e54953
VL  - 13
KW  - cancer
KW  - cancer-related pain
KW  - neoplasm-related pain
KW  - opioid analgesics
KW  - opioids
KW  - pain
AB  - Background: Opioids are a key component of pain management among patients with metastatic cancer pain. However, the evidence base available to guide opioid-related decision-making in individuals with advanced cancer is limited. Patients with advanced cancer or cancer that is unlikely to be cured frequently experience pain. Opioids are a key component of pain management among patients with metastatic cancer pain. Many individuals with advanced cancer are now living long enough to experience opioid-related harm. Emerging evidence from chronic noncancer pain literature suggests that longer-term opioid therapy may have limited benefits for pain and function, and opioid-related harms are also a major concern. However, whether these benefits and harms of opioids apply to patients with cancer-related pain is unknown. Objective: This manuscript outlines the protocol for the “Opioid Therapy for Pain in Individuals With Metastatic Cancer: The Benefits, Harms, and Stakeholder Perspectives (BEST) Study.” The study aims to better understand opioid decision-making in patients with advanced cancer, along with opioid benefits and harms, through prospective examination of patients’ pain experiences and opioid side effects and understanding the decision-making by patients, care partners, and clinicians. Methods: This is a multicenter, prospective cohort study that aims to enroll 630 patients with advanced cancer, 20 care partners, and 20 clinicians (670 total participants). Patient participants must have an advanced solid cancer diagnosis, defined by the American Cancer Society as cancer that is unlikely to be cured. We will recruit patient participants within 12 weeks after diagnosis so that we can understand opioid benefits, harms, and perspectives on opioid decision-making throughout the course of their advanced cancer (up to 2 years). We will also specifically elicit information regarding long-term opioid use (ie, opioids for ≥90 consecutive days) and exclude patients on long-term opioid therapy before an advanced cancer diagnosis. Lived-experience perspectives related to opioid use in those with advanced cancer will be captured by qualitative interviews with a subset of patients, clinicians, and care partners. Our data collection will be grounded in a behavioral decision research approach that will allow us to develop future interventions to inform opioid-related decision-making for patients with metastatic cancer. Results: Data collection began in October 2022 and is anticipated to end by November 2024. Conclusions: Upon successful execution of our study protocol, we anticipate the development of a comprehensive evidence base on opioid therapy in individuals with advanced cancer guided by the behavioral decision research framework. The information gained from this study will be used to guide interventions to facilitate opioid decisions among patients, clinicians, and care partners. Given the limited evidence base about opioid therapy in people with cancer, we envision this study will have significant real-world implications for cancer-related pain management and opioid-related clinical decision-making. International Registered Report Identifier (IRRID): DERR1-10.2196/54953 
SN  - 1929-0748
UR  - https://www.researchprotocols.org/2024/1/e54953
UR  - https://doi.org/10.2196/54953
UR  - http://www.ncbi.nlm.nih.gov/pubmed/38478905
DO  - 10.2196/54953
ID  - info:doi/10.2196/54953
ER  -